0 antall prosjekter

Dato fra ny til gammel

KREFT-Offentlig kreftprogram

CD20-specific T cell receptors in gene therapy of leukemia and lymphoma

T-cellereseptorer kan sammenlignes med målstyrte raketter, og utgjør den delen av T-cellene som gjør dem i stand til å gjenkjenne og drepe virusinfiserte celler med stor effektivitet og spesifisitet. Derfor kan T-celler effektivt kurere influensa uten bivirkninger. Prosjektet utnytter disse egens...

Tildelt: kr 7,6 mill.

Prosjektperiode: 2009-2015

Sted: Oslo

KREFT-Offentlig kreftprogram

Molecular alterations and targeted therapy in Endometrial Cancer

Endometrial carcinoma is the most common pelvic gynecologic malignancy. Methods for effective selection of patient at risk for metastasis, improved treatment for metastatic endometrial carcinoma and reliable predictive markers for response to new targeted therapeutics are urgently needed. This p...

Tildelt: kr 7,0 mill.

Prosjektperiode: 2009-2014

Sted: Vestland

KREFT-Offentlig kreftprogram

Molecular and biological characterization of cancer metastases

Purpose: Metastasis is the principal cause of cancer death, and for most tumor types staging, prognostication and therapy is inadequate. Hence, new knowledge on how to prevent metastasis and identification of predictive markers is among the most important challenges in cancer research. Our strat...

Tildelt: kr 6,7 mill.

Prosjektperiode: 2009-2013

Sted: Oslo

KREFT-Offentlig kreftprogram

Integration of clinical and basic research to improve treatment of multiple myeloma

Multiple myeloma is due to clonal expansion of malignant plasma cells. The incidence in the Nordic countries is approximately 6 new cases per 100,000 per year, which corresponds to nearly 20% of all haematological cancers. Approximately 300 people are gi ven this diagnosis each year in Norway. I...

Tildelt: kr 5,8 mill.

Prosjektperiode: 2009-2013

Sted: Trøndelag - Trööndelage

KREFT-Offentlig kreftprogram

Understanding Breast Cancer Genomics; Towards combined molecular profiles for better diagnosis and treatment

We seek to reach a more fundamental understanding of the biological dynamics of breast cancer. High-throughput molecular data at multiple levels (eg DNA, mRNA, miRNA and protein level) have become available on increasing numbers of patients, and various m olecular profiles have been associated wi...

Tildelt: kr 10,5 mill.

Prosjektperiode: 2009-2012

Sted: Oslo

KREFT-Offentlig kreftprogram

Aspects of breast cancer risk: subtypes of breast cancer, relation to angiogenic factors and gene-environment interactions

Det er kjent at brystkreftsykdommen kan inndeles i ulike undergrupper eller subtyper, men det er ikke kjent om "tradisjonelle" risikofaktorer har ulik sammenheng med ulike subtyper. Derfor har vi undersøkt sammenhengen mellom kjente risikofaktorer og seks ulike subtyper av brystkreft, identifise...

Tildelt: kr 5,1 mill.

Prosjektperiode: 2009-2014

Sted: Trøndelag - Trööndelage

KREFT-Offentlig kreftprogram

Somatic, translational and psychosocial research in long-term cancer survivors

Background: The number of long-term cancer survivors (LTCSs) (>5 years after primary treatment) is rapidly increasing and currently concerns >100,000 patients in Norway. Although frequently cured by their disease, the treatments and the cancers have late effects that impair the physical and ment...

Tildelt: kr 5,2 mill.

Prosjektperiode: 2009-2015

Sted: Oslo

KREFT-Offentlig kreftprogram

Development of biomarkers and identification of therapeutic targets for prostate carcinogenesis

Prostate cancer is the most common noncutaneous malignancy and the second leading cause of cancer mortality in men in western countries, including Norway. Prostate cancer encompasses a biological continuum from a slow-growing indolent tumour to a highly a ggressive and potentially fatal form. A m...

Tildelt: kr 4,5 mill.

Prosjektperiode: 2009-2013

Sted: Oslo

KREFTSATS-Særutlysning kreftmidler, historikk

Translational research directed toward identification of the mechanisms of chemoresistance in breast cancer.

Our group conducts translational research with the primary aim of identifying the mechanisms of resistance to chemotherapy in breast cancer. We have concentrated our work on alterations in genes participating in the p53 and retinoblastoma protein pathway as cause of anthracycline resistance. In ...

Tildelt: kr 3,6 mill.

Prosjektperiode: 2009-2012

Sted: Vestland

KREFT-Offentlig kreftprogram

EURAMOS- KREFT

...

Tildelt: kr 0,73 mill.

Prosjektperiode: 2005-2013

Sted: Oslo

KREFTSATS-Særutlysning kreftmidler, historikk

MOLECULAR AND BIOLOGICAL STUDIES OF CANCER METASTASIS

Metastasis, cancer spread to other organs, is the principle cause of death of cancer patients. Early detection of metastatic tumor cells, development of new treatment strategies and knowledge about how to prevent cancer metastasis are some of the most cha llenging tasks in cancer research. Our pr...

Tildelt: kr 6,0 mill.

Prosjektperiode: 2005-2009

Sted: Oslo

KREFTSATS-Særutlysning kreftmidler, historikk

Vaccination against B cell cancers: from experimental immunology to patients

Aim: The goal is to improve the prognosis of patients with multiple myeloma and B cell lymphoma by vaccination with a recombinant antibody-like vaccine (Vaccibodies). Background: B cell tumors produce a highly tumor-specific antigen, monoclonal immunoglob ulin with unique variable(V) regions, tha...

Tildelt: kr 3,8 mill.

Prosjektperiode: 2005-2008

Sted: Oslo

KREFTSATS-Særutlysning kreftmidler, historikk

Novel therapeutic strategies for stimulation of anti-neoplastic immune activity

More than 20% of the human genome encodes proteins that are devoted to cellular signalling. Signal networks that involve the signal molecule cyclic AMP (cAMP) are involved in diseases such as cancer, cardiovascular disease, type II diabetes, obesity, HIV and asthma. Cyclic AMP acts as an acute in...

Tildelt: kr 6,0 mill.

Prosjektperiode: 2005-2007

Sted: Oslo

KREFTSATS-Særutlysning kreftmidler, historikk

GENOME MAINTENANCE MECHANISMS AND THEIR ROLE IN PREVENTING CANCER DEVELOPMENT

DNA repair genes represent a class of tumor suppressor genest hat have proven increasingly important in preventing cancer development in humans. This is not unexpected as DNA repair has been demonstrated to have a crucial role in maintaining genome stabil ity. DNA damage induced by cellular expos...

Tildelt: kr 6,6 mill.

Prosjektperiode: 2005-2007

Sted: Trøndelag - Trööndelage

KREFTSATS-Særutlysning kreftmidler, historikk

Retinoids, antioxidants and cancer

Retinol and its metabolites (vitamin A, retinoids) orchestrates proliferation and differentiation through its nuclear retinoic acid receptors. Antioxidants have also recently been implied in regulation of cell signalling and gene transcription. There exis t convincing evidence that diets high in ...

Tildelt: kr 7,0 mill.

Prosjektperiode: 2004-2007

Sted: Oslo

KREFTSATS-Særutlysning kreftmidler, historikk

Genetic predictors of mammographic density

Mammographic density represents a strong and independent breast cancer risk factor, and possibly a useful surrogate endpoint for breast cancer risk. Mammographic density decreases when women undergo menopause or start tamoxifen therapy, but increases in w omen starting postmenopausal hormone ther...

Tildelt: kr 3,9 mill.

Prosjektperiode: 2004-2009

Sted: Oslo

KREFTSATS-Særutlysning kreftmidler, historikk

Early life factors and adult cancer risk

In this proposal, we describe three separate studies. First, in a cohort study of more than 35,000 men and women born between 1920 and 1958, we propose to use historical data from birth records to study the association between perinatal factors (primaril y birth weight and birth length) and risk...

Tildelt: kr 4,8 mill.

Prosjektperiode: 2004-2008

Sted: Trøndelag - Trööndelage

KREFTSATS-Særutlysning kreftmidler, historikk

The Norwegian Women and Cancer post genome cohort study - NOWAC

The NOWAC post-genome study is an integrated collaboration between epidemiologists, clinicians and basic genetic scientists. The cohort is an extension of the existing nationwide NOWAC prospective study with 130,000 participants. 1. During the years 2003 -6 we will build a "core cohort" of 50,00...

Tildelt: kr 4,2 mill.

Prosjektperiode: 2004-2008

Sted: Troms - Romsa - Tromssa

KREFTSATS-Særutlysning kreftmidler, historikk

Critical regulatory networks for tumor-vascular interactions and activated angiogenesis in urogenital cancers

Angiogenesis and tumor-vascular interactions are essential for tumor spread. We focus on this aspect since anti-angiogenic therapy avoid treatment resistance. Adhesion molecules are important for the ability of tumor cells to invade surrounding tumor stro ma and to enter the vascular systems (blo...

Tildelt: kr 6,6 mill.

Prosjektperiode: 2004-2009

Sted: Vestland

KREFTSATS-Særutlysning kreftmidler, historikk

Developmental biology of solid tumours may pave the way for advanced medicine

We study three human cancer diseases, colorectal cancer (CRC), testicular germ cell tumour (TGCT), and malignant peripheral nerve sheath tumour (MPNST), originating from different types of stem cells. All three diseases develop through morphologically def ined stages, and the stepwise molecular b...

Tildelt: kr 6,6 mill.

Prosjektperiode: 2004-2009

Sted: Oslo

KREFTSATS-Særutlysning kreftmidler, historikk

Molecular mechanisms of androgen action and prostate carcinogenesis

...

Tildelt: kr 0,75 mill.

Prosjektperiode: 2004-2005

Sted: Oslo

KREFTSATS-Særutlysning kreftmidler, historikk

Opioids, Symptom Management and Palliation Research Group

The group was formally established in 2002 thanks to a research grant from Norwegian Research Council (NFR) (2001-2003). The group consist of core personnel in permanent positions at The Faculty of Medicine, NTNU and personnel supported by the above NFR grants and other grants including NFR. T...

Tildelt: kr 8,8 mill.

Prosjektperiode: 2004-2009

Sted: Trøndelag - Trööndelage

KREFTSATS-Særutlysning kreftmidler, historikk

Molecular mechanisms of androgen action and prostate carcinogenesis

Androgens have a pivotal role in the development and maintenance of the male reproductive system, the normal prostate, as well as the initiation and progression of prostate cancer . Prostate cancer is the most commonly diagnosed non-cutaneous cancer and s econd leading cause of cancer death in me...

Tildelt: kr 5,9 mill.

Prosjektperiode: 2004-2008

Sted: Oslo

KREFTSATS-Særutlysning kreftmidler, historikk

Nutrients, gene regulation and cancer

...

Tildelt: kr 6,0 mill.

Prosjektperiode: 2001-2004

Sted: Oslo

KREFTSATS-Særutlysning kreftmidler, historikk

The "Norwegian Women and Cancer Study" - a representative population based prospective study

...

Tildelt: kr 6,0 mill.

Prosjektperiode: 2001-2004

Sted: Troms - Romsa - Tromssa

KREFTSATS-Særutlysning kreftmidler, historikk

Integration of clinical and basic research to improve treatment of multiple myeloma

Formålet er økt integrasjon av forskning og behandling av kreftsykdommen myelomatose gjennom følgende delprosjekter: 1. Ødeleggelse av skjelettet ved myelomatose er et hovedproblem ved sykdommen. Prosjektet undersøker hvorledes faktorer i blod og benm arg påvirker bensykdommen. Osteoprotegeri...

Tildelt: kr 7,3 mill.

Prosjektperiode: 2001-2005

Sted: Trøndelag - Trööndelage

KREFTSATS-Særutlysning kreftmidler, historikk

Biological, diagnostic and therapeutic aspects of cancer metastasis

...

Tildelt: kr 8,8 mill.

Prosjektperiode: 2001-2005

Sted: Oslo

KREFTSATS-Særutlysning kreftmidler, historikk

Intergrated basic and clinical research on pain treatment in cancer

...

Tildelt: kr 9,5 mill.

Prosjektperiode: 2000-2004

Sted: Trøndelag - Trööndelage

KREFTSATS-Særutlysning kreftmidler, historikk

Perinatal and Adolescent Risk Factors for Breast Cancer

...

Tildelt: kr 3,2 mill.

Prosjektperiode: 2000-2005

Sted: Trøndelag - Trööndelage

KREFTSATS-Særutlysning kreftmidler, historikk

Molecular mechanisms of androgen action in prostate cancer

...

Tildelt: kr 9,5 mill.

Prosjektperiode: 2000-2005

Sted: Oslo

1 2